| __timestamp | Bristol-Myers Squibb Company | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 5699000000 | 504755000 |
| Thursday, January 1, 2015 | 5001000000 | 838526000 |
| Friday, January 1, 2016 | 5002000000 | 1177697000 |
| Sunday, January 1, 2017 | 4849000000 | 1320433000 |
| Monday, January 1, 2018 | 4551000000 | 1556200000 |
| Tuesday, January 1, 2019 | 4871000000 | 1834800000 |
| Wednesday, January 1, 2020 | 7661000000 | 1346000000 |
| Friday, January 1, 2021 | 7690000000 | 1824900000 |
| Saturday, January 1, 2022 | 7814000000 | 2115900000 |
| Sunday, January 1, 2023 | 7772000000 | 2631300000 |
| Monday, January 1, 2024 | 8414000000 | 2954400000 |
Igniting the spark of knowledge
In the ever-evolving pharmaceutical industry, understanding the financial strategies of leading companies is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Bristol-Myers Squibb Company and Regeneron Pharmaceuticals, Inc. from 2014 to 2023. Over this period, Bristol-Myers Squibb consistently outspent Regeneron, with its SG&A expenses peaking in 2022 at approximately 7.8 billion dollars, a 70% increase from 2014. In contrast, Regeneron saw a more dramatic rise, with expenses growing over 400% from 2014 to 2023, reaching around 2.6 billion dollars. This trend highlights Bristol-Myers Squibb's established market presence and Regeneron's aggressive growth strategy. As these companies navigate the competitive landscape, their SG&A spending reflects broader strategic priorities, from market expansion to operational efficiency.
Operational Costs Compared: SG&A Analysis of Johnson & Johnson and Bristol-Myers Squibb Company
Merck & Co., Inc. vs Regeneron Pharmaceuticals, Inc.: SG&A Expense Trends
Bristol-Myers Squibb Company or Zoetis Inc.: Who Manages SG&A Costs Better?
Bristol-Myers Squibb Company or Vertex Pharmaceuticals Incorporated: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Bristol-Myers Squibb Company vs Neurocrine Biosciences, Inc.
Bristol-Myers Squibb Company and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Bristol-Myers Squibb Company and Agios Pharmaceuticals, Inc.
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Blueprint Medicines Corporation Trends and Insights
Selling, General, and Administrative Costs: Regeneron Pharmaceuticals, Inc. vs Bio-Techne Corporation
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Corcept Therapeutics Incorporated Trends and Insights
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Merus N.V.
SG&A Efficiency Analysis: Comparing Regeneron Pharmaceuticals, Inc. and Amphastar Pharmaceuticals, Inc.